Up Close with Glofitamab
Last Updated: May 16, 2025
Discover more about glofitamab-gxbm (COLUMVI™).
Related Resources:
PQI
PQI: Glofitamab-gxbm (COLUMVI®) for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
Last Updated: 01/12/2024
Perspectives
OncolyticsToday: The Bispecific Antibody Revolution
Author: KELLY BRUNK
Last Updated: 04/01/2024
Find Similar Resources:
Immunotherapy
Immunotherapy
Immunotherapy
Immunotherapy
Overview of BTCEs: Comparison of Bispecific T-Cell Engagers (BTCEs)
Last Updated: 09/09/2026
Up Close with Linvoseltamab
Last Updated: 06/29/2026
Example SOPs and Documents: Transitioning Patients on Bispecific T-Cell Engagers Between Care Settings
Last Updated: 07/01/2025
Example SOPs and Documents: Bispecific T-cell Engager Billing Procedure
Last Updated: 07/01/2025
PQI
Patient Education Sheet
Patient Education Sheet
Patient Education Sheet
PQI: Tafasitamab-cxix (Monjuvi) for Relapsed/Refractory Follicular Lymphoma
Last Updated: 09/10/2026
Emapalumab
Last Updated: 09/08/2026
Infliximab
Last Updated: 09/08/2026
Obinutuzumab and Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
Last Updated: 09/08/2026